Aggressive B-cell non-Hodgkin's lymphoma (NHL)

Clinical trials for Aggressive B-cell non-Hodgkin's lymphoma (NHL) explained in plain language.

Never miss a new study

Get alerted when new Aggressive B-cell non-Hodgkin's lymphoma (NHL) trials appear

Sign up with your email to follow new studies for Aggressive B-cell non-Hodgkin's lymphoma (NHL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Completed 1

New drug combo shows promise for tough blood cancers in early trial

Disease control Completed

This early-stage study tested a new drug called PRT2527, alone or with other cancer drugs (zanubrutinib or venetoclax), in 86 people with various blood cancers that had returned or stopped responding to standard treatments. The main goals were to check safety, find the best dose,…

Matched conditions: AGGRESSIVE B-CELL NON-HODGKIN'S LYMPHOMA (NHL)

Phase 1 • Sponsor: Prelude Therapeutics • Aim: Disease control

Last updated Jun 27, 2026 08:14 UTC

Aggressive B-cell non-Hodgkin's lymphoma (NHL)

Get alerted when new Aggressive B-cell non-Hodgkin's lymphoma (NHL) trials appear

New drug combo shows promise for tough blood cancers in early trial